Thursday, August 11, 2022
News
NEWS HOME
»
PRN INDIA
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
  SocialTwist Tell-a-Friend  
   

  • Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 in Europe
  • Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents

GAITHERSBURG, Md., June 23, 2022 /PRNewswire/ --  Novavax,  Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 PREVENT-19 clinical trial.

"This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax.

The CHMP recommendation was based on data from the ongoing pediatric expansion  of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. Fever was seen more frequently in adolescents than in adults. These effects are usually mild or moderate and improve within a few days from the vaccination.

The European Commission (EC) granted CMA for Nuvaxovid to prevent COVID-19 in people 18 years of age and over in December 2021.

In the 12 through 17 year-old population, emergency use authorization  has been granted in India.

Authorization in the U.S.

The Novavax COVID-19 vaccine (NVX-CoV2373) has not yet been authorized for use in the U.S. and the trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.

Important Safety Information
  • Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  • Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
  • Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
  • Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
  • The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
  • Individuals may not be fully protected until seven days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
  • The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.

For additional information on Nuvaxovid, please visit the following websites:

About NVX-CoV2373    

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.  

The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2 °- 8 ° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.  

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.  

About the NVX-CoV2373 Phase 3 Trials

NVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.  

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).  

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.  

PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement (# MCDC2011-001).  

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in  NEJM.  

About Matrix-M™ Adjuvant  

Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.  

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. 

For more information, visit www.novavax.com and connect with us on LinkedIn.  

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. 

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational combination vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Alex Delacroix | 240-268-2022
ir@novavax.com

Media
Ali Chartan | 240-720-7804
media@novavax.com

Novavax Logo

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

More News by PR Newswire India

DENTSU RECOGNIZED AS A STRONG PERFORMER IN GLOBAL MARKETING SERVICES REPORT BY INDEPENDENT RESEARCH FIRM

Deltek Announces Speakers and Sponsors for Deltek ProjectCon 2022

Yellow.ai announces the launch of its proprietary DynamicNLP™, a first in the enterprise Conversational AI space

TUMI announced as Official Luggage Partner of Tottenham Hotspur Women's Pre-Season Tour

WITH 40+ NEW INSTALLATIONS, QATAR PRESENTS MORE THAN 100 MAJOR WORKS OF PUBLIC ART AHEAD OF THE FIFA WORLD CUP QATAR 2022™

NuraLogix researchers announce AI models that can predict Metabolic Risks

A TROPICAL ESCAPE WITH ULTIMATE EXPERIENCES AT THE RITZ-CARLTON, BALI

CU UCRD's bio-insecticide to revolutionise India's fruit production

No-Code DevOps platform Humalect raises $ 750k in seed round led by StartupXseed Ventures

ONE Advertising - the creative force behind Divya Bhaskar's Sachi Vaat Bedhadak campaign

Sennheiser announced exciting deals on its best-selling products during the Amazon Great Freedom Festival Sale 2022

YES BANK and IBSFINtech tie up to provide enhanced digital services for corporate clients

Multi-Blockchain Wallet App Nufinetes Releases New Feature to View NFTs on Ethereum and VeChain

impress.ai and Aon to help employers improve hiring accuracy, streamlining the end-to-end recruitment process

Shivalik Bimetal posts solid Q1FY23 top and bottom lines YoY, on the back of resurging global demand

Edvoy CEO, Sadiq Basha, named Visionary Entrepreneur of the Year 2022 by WPI

Indo Amines Limited declares tremendous growth, Operational Revenue up by 46%

Over 550,000 people set to attend the International Saudi Falcons and Hunting Exhibition in Malham, Riyadh

HPL Electric and Power Ltd reports solid Q1FY23 Results

Spinny's Take on the Swiftly Changing Automobile Industry

World's Largest Fintech Conference is Back

15th Singapore International Energy Week (SIEW) Registration Now Open

Indian WWW Treatment Market to Experience a Boom as the Country witnesses increase in Private Investments

Khadim India records 190% growth in Retail Sales in Q1 FY 23

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Adda52 announces 'Freedom Fest' - an online Poker tournament to celebrate 75 years of Independence

Online Proctoring Solution Provider Shinkan Launches Shinkan Edge To Revolutionise Corporate Recruitment

The 49th CIFF Guangzhou Presents the Entire Furniture Supply Chain to 50 Million Visitors Online and Offline

Xinhua Silk Road: N.China's Lingqiu County takes organic agriculture as effective way to promote rural development

EARTHDAY.ORG'S THE CANOPY PROJECT ANNOUNCES MANGROVE PLANTING PROJECT IN BANGLADESH WITH CRYSTAL INTERNATIONAL GROUP LIMITED

Here and Now, There and Then: Prince Mohammad Bin Fahd University Drives Innovation and Invention, Locally and Globally

Global supply chain reconfiguration to persist through 2030

Hakuhodo and DAC launch H+, a strategic group to "Empower Your Digital Future" with one of APAC's most distinctively audience-centric data marketing approaches

ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE

Recorded Future Launches National Cyber Defense Intelligence Kit

Launched to immediate global acclaim via Livestream: Absen's pioneering KLCOB Micro LED product series

SEMI Applauds President Biden's Signing of CHIPS and Science Act of 2022

Anthony Di Iorio Opens Whitelist for New Global Project to Empower a User-Controlled Internet; Project to Be Unveiled November 3

New measures agreed to strengthen the partnership between Mongolia and China

Focused Photonics Inc. Selects Wolters Kluwer CCH® Tagetik Expert Solution for its Disclosure Management Needs

Snapmaker Announces Artisan 3-in-1 3D Printer is Available for Pre-order Today

Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth

DevOps Institute Releases First Ever 'Global SRE Pulse 2022' Report

WorkForce Software Honored Alongside IBM and Google in Comparably's Annual Ranking of Top Companies for Having the Best Leadership Team

Aon appoints James Platt as Chief Digital Officer and Mindy Simon joins the firm as Chief Operating Officer

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

Satellite Software Innovator Antaris Announces Close of $4.2 Million Seed Funding Round to Accelerate Development of Software Solutions for Space

GOLDIAM reports its Q1FY23 results, share of Lab grown diamond & jewellery strengthens further

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

Nobu Hospitality Expands its Footprint in Asia Pacific

Gunzilla Games Raises $46M to Redefine the Battle Royale Genre By Letting Players Trade Their In-Game Items in "Off The Grid"

Deepak Nitrite Demonstrates Strong Topline Performance with 35% Y-o-Y Growth

A leading ERP company, Focus Softnet eyes revenues of 160 crores, projects a growth of about 20% Y-O-Y

Quest Global Becomes Arm Approved Design Partner

GCLSI Receives French Carbon Footprint Certification for Its 182 and 210 Series of Photovoltaic Modules

Triumph International India launches their first exclusive retail store in Pune

Indian Ice-Cream Manufacturers' Association (IICMA) met with Finance Minister Nirmala Sitharaman to discuss GST rates on supply of ice cream by ice cream parlours in India

Dyninno opens new office in Cyber City; Plans more offices in Gurugram and Mumbai

Woxsen University bestows Chair Professorships in honour of International Experts

People Matters TechHR 2022 Brings Fresh Eyes to the World of HR

PACORR Launches Melt Flow Index Tester - Fully Automatic Version

RateGain Launches Airline Travelers' Forecast to Help Commercial Teams Drive Higher ROI

Thai Digital Content Gaining Increasing Recognition Around the World

Crave InfoTech launches White Paper on Top Supply Chain Challenges

GRL accelerates the authorization of biometrics devices for Government of India projects

Everest Group Names Automation Anywhere a Leader in the inaugural Task Mining PEAK Matrix® Assessment 2022

China Wuling's First Global Electric Vehicle Air ev Rollouted, First Step In Indonesia

FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

GIGABYTE Releases 600 series BIOS updates ready for Intel's upcoming new-gen processors

Soroco Named a Leader in Everest Group's PEAK Matrix® for Task Mining Technology Provider 2022

Starburst Celebrates 10th Anniversary of Trino

Point-of-Care Ultrasound Certification Academy to Host World Conference

The "Picturesque and Dynamic Zhejiang" Global Short Video Competition Launches

BlackBerry Commended by Frost & Sullivan for Optimizing Edge-to-cloud Performance, Security, Privacy, and Scalability with its IVY Platform for Automakers

Amwell Applauded by Frost & Sullivan for its Comprehensive Digital Care Delivery Enablement Platform, Converge™

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Axis Bank in partnership with CRMNEXT wins the Best CRM Implementation Award by Asian Banker

Godrej Properties Ltd. unveils insights from Home Livability Factors research

Gear Up with All New Helix Metalfit 3.0 Smartwatch Launched by Timex Group India

Roundtable with Leading Doctors and Youth Aims for a Tobacco-Free Future for India

Catalytic Investment to Improve Community Health Care for Millions Across Africa

DIFC Launches First Global Family Business and Private Wealth Centre

2022 ITOE - Home Lifestyle Expo Opens, Provides Strong Impetus for Development of Digital Trade

FRIMLINE LAUNCHES INDIA'S 1st ORAL CARE RANGE FOR PREGNANT WOMEN

Aptus Value Housing Finance India Limited announces Q1 FY23 Results

Tata Communications enhances InstaCC™ Platform with digital features

/C O R R E C T I O N -- Lentra/

Leading Solar Energy Solution Provider Haitai Solar Launches IPO on Beijing Stock Exchange

Kiko Live to be launched on ONDC in September

Clarivate Selected by Singapore's National Library Board to Play a Part in Building Libraries of the Future

TCL Reaffirms its Leadership in Mini LED TVs in 2022

NID Foundation unveils Heartfelt-The Legacy of Faith; A book showcasing PM Modi's relationship with the Sikh community at Melbourne

AirCarbon Exchange Offsets Emissions Through to December 2023

Celebrate independence from the worries of interest rates with Tata Housing Development Company's 'Its Interesting' campaign with 3.50% interest rate for 12 months in the 75th year of Independence

Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development

M/V Riva Wind and M/V Arizona Both Sail from Ukraine with 105,000 Tons of Grain

Atlanta Site Strengthens Sims Lifecycle Services' Operational Footprint

PRA Group Leader LaTisha Tarrant Named Chief Human Resources Officer

Media Advisory - BMO Financial Group to Announce its Third Quarter 2022 Results

Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

GACL Financial results for the first quarter ended 30th June 2022

Strong Technical Advantages of TANK Platform, GWM TANK300 Will Bring a New Intelligent Off-road Experience

Bitget Launches $200 Million Protection Fund To Safeguard Users' Asset Security

Chandigarh University joins hands with Punjab Remote Sensing Centre for resources management and disaster mitigation

Saudi Arabia to Bid for the 2026 AFC Women's Asian Cup

FIRMENICH DELIVERS RECORD RESULTS DESPITE CHALLENGING MACRO-ECONOMIC ENVIRONMENT

A Center of Hope and New Life

CHAIRMAN OF ATLAS CORP., FAIRFAX FINANCIAL HOLDINGS LIMITED AND THE WASHINGTON FAMILY PARTNER WITH OCEAN NETWORK EXPRESS PTE. LTD. TO JOINTLY PROPOSE ACQUIRING ALL COMMON SHARES OF ATLAS CORP. NOT CONTROLLED BY ITS MAJORITY SHAREHOLDERS FOR $14.45 PER SHARE IN CASH

Hon'ble Prime Minister Modi inaugurates multispecialty charitable Shrimad Rajchandra Hospital; a revolution in rural healthcare

PARAMOUNT PICTURES' "TOP GUN: MAVERICK" FLIES PAST $50 MILLION IN SCREENX AND 4DX

Empowering Young Women and Refugees Worldwide through STEM & Sustainability

ViewSonic's Visual Solutions Ignite Love and Hope in 2022 World Women's Art Festival

Besrey Celebrates Seventh Anniversary with Giveaways and Gifts for Parents

ADVENTURERS ROSS EDGLEY AND KATIE TUNN OPEN DOORS AT NEW TALISKER VISITOR EXPERIENCE

Frost & Sullivan Institute lauds Global Companies with Prestigious Enlightened Growth Leadership Awards

Oracle Names WorkForce Software the Cloud HCM ISV Partner of the Year as Winner of the 2021 Oracle Cloud HCM HR Heroes Visionary Award

In a first of its kind, Rural Banking Outlets in India to get a distinct identity through 'RedBlue Revolution'

Titan.ium Platform, LLC Announces 5G SA Evolution of NetCore to Expand Its Private Networks Solutions

Dentsu Group Acquires a Majority Stake in Extentia to Strengthen Customer Transformation and Technology Capabilities

Agility Completes £763 Million Acquisition of Menzies Aviation

Elearnmarkets goes global with their 2nd edition of the Face2Face Trading Conclave in Bangkok

Global Tree presents Study Fair 2022

Innoviti joins ONDC platform to help small sellers accelerate sales through co-promotion opportunities with banks and brands

VNPT Group partners with Comviva to deliver advanced digital customer experience

SVKM'S NMIMS Shirpur campus bags NBA accreditation for School of Pharmacy & Technology Management

Crest, an Inventory Planning Tool Gets Funding from Its first 2 Customers, Sirona Hygiene and Samosa Party

Panchshil Realty To Sponsor Accomplished Mountaineer Baljeet Kaur's Next Adventure

The Adecco Group: HALF YEAR REPORT 2022

The Adecco Group: Q2 22 Results - Market share momentum, solid growth and margin

Cielo continues global expansion, opens new office in India

VCTI Achieves Dramatic Growth Fueled by U.S.'s Plans and Funding for Broadband Expansion

Sun Life Appoints Chris Wei to EVP and Chief Client and Innovation Officer

ROSHN signs agreement to sponsor and rename Jeddah Waterfront

GameChange Solar Announces 6 GW Midwest Tracker Factory, Increases USA Capacity to 14 GW

Franklin Templeton, Inc. Renews with Empire State Realty Trust for 79k Square Feet at 100 First Stamford Place

Music industry veteran Lefroy Verghese joins Audio Network

Women's World Banking Announces 2023 Fintech Innovation Challenge to Elevate Fintechs with New Solutions to Close the Gender Gap in Financial Services

KPM Analytics Introduces New Discrete Analyzer to Complete Its SmartChem® Product Line

HAVAS HEALTH & YOU PARTNERS WITH REPUBLICA HAVAS TO CREATE REPUBLICA HAVAS HEALTH

Collaboration of ePayLater, the SME Credit Platform with JioMart Partner

Firmenich Appoints Maurizio Clementi ad interim President of its Taste & Beyond Division

Enfinity Global closes $242 million of long term financing for three operational solar power plants in Japan

HIGHLIGHTS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022

HISTORY OF HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO INCREASED RISK OF DEMENTIA

HarperCollins Publishers India is proud to announce the forthcoming publication of Chitra Banerjee Divakaruni's new novel INDEPENDENCE

Waterborne Trade in Rio South Texas

A Bond Tightly Woven Together With Sneh - An Exquisite Rakhi Range From Ferns N Petals (FNP)

FMCG and Consulting companies top recruiters at SPJIMR Autumn Internship 2022

Jury unveiled for UXplorer'22; features design industry stalwarts from India and abroad

Hisense Shines in UEFA Women's EURO 2022™, Achieved Champion Position in Global Market

The Israeli Ministry of Defense Selects Mona's Enterprise Monitoring Solution to Gain Complete Visibility into Their AI / ML Systems

Over 22% of small businesses that availed loans in FY 2022 were run by women: NeoGrowth Social Impact Report

FORTUNE RELEASES ANNUAL FORTUNE GLOBAL 500 LIST

Technology Solutions to Boost Employee Experience and Improve Patient Outcomes

Cendyn announces acquisition of digitalhotelier

Credgenics launches Digital Collections Technology Platform in Indonesia

MOMENTUM NAMED A BEST COMPANY TO WORK FOR WITH "OUTSTANDING" LEVELS OF WORKPLACE ENGAGEMENT

Zimyo at-service with its 'Start-up Program'

Sanjay Ghodawat conferred with the Maharashtra Leadership Award 2022

Jio Platforms partners with Subex HyperSense AI to augment its 5G product line

Globalization Partners Again Named an Industry Leader in NelsonHall's 2022 Global Employer of Record Research

Detect Technologies announces global agreement with Vedanta

CLA Nearly Triples Office Space with ESRT at One Grand Central Place

Sparrow Introduces Newly Updated Sparrow Cloud and Sparrow SCA at Black Hat USA 2022

CELEBRATING CULTURAL REVIVAL AND THE TRADITION OF PASSING ON GENERATIONAL KNOWLEDGE THROUGH A NEW ROYAL CANADIAN MINT COIN HONOURING THE RED RIVER MÉTIS

LOWER SOCIOECONOMIC STATUS IN CHILDHOOD, PERSISTENT LOW WAGES LINKED TO RISK FOR DEMENTIA AND FASTER MEMORY DECLINE

Expel Applauded by Frost & Sullivan for Enabling Managed and Automated Threat Detection and Response

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Bigtincan Unveils Analytics Experience and Delivers Enhancements to Award-Winning Sales Enablement Platform

Zift Solutions Marks Six Years of SOC 2 Compliance

Adorable has a new meaning with Little Surprise Box the pioneers of Kids Monsoon Fashion in India

Firmenich Announces Grand Opening of West Coast Pilot Plant for Food & Beverage Customers

Leica Camera engages in the Laser TV equipment segment and agrees on technological cooperation with Hisense

Metabolon Awarded ISO 9001:2015 Recertification

At Chandigarh University, multiple scholarships worth Crores of rupees help talented and meritorious students overcome the barrier of weaker economic situation

Altair Announces Winners of 10th Annual Enlighten Award

iHerb Achieves Customer Service Milestones

10,000 RMB! "My Guangdong Story" short video solicitation calls for global entries

STL launches comprehensive optical suite for India's 5G readiness

LambdaTest's intelligent test orchestration platform HyperExecute is now available on the Microsoft Azure Marketplace

Northwest Analytics Applauded by Frost & Sullivan for Preventing Institutional Knowledge Loss and Bridging Skills Gaps with NWA Analytics Knowledge Suite™

New Research Reveals Risk Factors to Business Success in a Post-Pandemic World

Comviva receives Mastercard Cloud Based Payments Certification

EZVIZ LAUNCHES TY1 With 4MP, A SMART Wi-Fi PAN and TILT CAMERA

Novel and fast typing method developed to control monkeypox by Molecular Biology Systems (MBS) in collaboration with the Amsterdam UMC and Danish Rigshospitalet

Intersec Reports Most Successful Fiscal Year In Company History

Protean forays into cyber security business, launches Protean InfoSec Services Limited

Prudent Corporate Advisory Services Limited Profits grew by 25% YoY & Flows from SIPs Reach Highest Ever in Q1FY23

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

SEERIST ESTABLISHES THE FIRST AUGMENTED ANALYTICS TECHNOLOGY FOR SECURITY AND THREAT INTELLIGENCE PROFESSIONALS

Quinnox named a Strong Performer in Modern Application Development Services by Independent Analyst Firm

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Nitish countered era of backdoor politic...
Nitish to prove majority in Bihar Assemb...
India became Independent when people too...
'Har Ghar Tiranga' campaign: Assam sold ...
YSRCP MP's video on social media not ori...
Maha: Independents, smaller parties fume...
More...    
 
 Top Stories
Kerala: Congress councillor arreste... 
Opposition trying to make headlines... 
Indigenous vaccine launched to prot... 
DGCA releases guidelines for medica... 
India needs to quadruple climate fi... 
Differences emerge in TRS over cand... 
Corbevax approved as heterologous v... 
Assam Orthodox tea fetches Rs 22K a...